SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
bcp12083-sup-0001-si.doc666K

Figure S1

WinBUGS model for the network meta-analysis (efficacy)

Figure S2

WinBUGS model for the network meta-analysis (tolerability)

Figure S3

Funnel plots (Revman v5.0) of randomized controlled trials comparing each AED vs. placebo as add-on treatment for refractory epilepsy for (A) efficacy (50% responder rate) and (B) tolerability [withdrawal from treatment due to intolerable adverse event(s)]

Table S1

Search strategy – MEDLINE (via PubMed)

Table S2

Limits applied within each database searched

Table S3

Criterion used within the systematic review

Table S4

Raw data extracted from clinical trials for the meta-analysis

Table S5

Year of introduction of AEDs to the European/US market (included within this review)

Table S6

Estimates of the summary relative risk (from the frequentist and Bayesian network meta-analysis) relating to responder rate and calculated NNT (from risk ratio) relative to placebo

Table S7

Estimates of the summary relative risk (from the frequentist and Bayesian network meta-analysis) relating to premature discontinuation rate and calculated NNH (from risk ratio) relative to placebo

Table S8

(A) Ranking of AEDs on the basis of efficacy (network meta-analysis estimates); (B) Ranking of AEDs on the basis of tolerability (network meta-analysis estimates); (c) Cost of 1 month's supply of each AED at the treatment dose used within the analysis (pound sterling, excluding VAT) (British National Formulary: Edition 63)

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.